• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

光感受器治疗后挽救动力学的空间和时间分辨率。

Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec.

机构信息

University Eye Hospital, Center for Ophthalmology, University of Tübingen, Tübingen, Baden-Württemberg, Germany.

Center for Rare Eye Diseases, University of Tübingen, Tübingen, Baden-Württemberg, Germany.

出版信息

Br J Ophthalmol. 2022 Jun;106(6):831-838. doi: 10.1136/bjophthalmol-2020-318286. Epub 2021 Jan 20.

DOI:10.1136/bjophthalmol-2020-318286
PMID:33472769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9132865/
Abstract

BACKGROUND

Voretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.

METHODS

Seven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months.

RESULTS

All except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R=0.5).

CONCLUSIONS

The presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function.

摘要

背景

Voretigene neparvovec 是一种基因治疗药物,用于治疗由双等位基因突变引起的视网膜营养不良。在这项研究中,我们报告了一种新的、客观的视网膜定位光感受器挽救评估方法。

方法

5 名患者(14、21、23、24、36 岁,1 名男性,4 名女性)的 7 只眼睛接受了 voretigene neparvovec 治疗。临床检查包括视力测试、暗适应全视野刺激阈值(FST)、暗适应色觉周边(DAC)30 度网格和 30 度网格暗适应和明适应色觉瞳孔Campimetry(CPC)。所有评估和频域光相干断层扫描均在基线、1 个月和 3 个月进行。

结果

除最年长的患者外,所有患者的杆状功能均有可测量的改善,通过 FST、DAC 或暗适应 CPC 进行评估。所有眼睛的视力略有提高或保持稳定。三例患者观察到光适应 CPC 测量的锥状功能改善。暗适应阈值的增益与蓝色 FST 和 DAC 刺激(青色)的平均值与年龄呈强相关性(R>0.7)。暗适应 CPC 中瞳孔反应的改善与基线局部视网膜体积呈正相关(R=0.5)。

结论

所提出的方案允许评估基因治疗效果的个体时空影响。此外,我们还探讨了与治疗成功相关的参数。CPC 和 DAC 提供了新的快速方法来评估杆状和锥状功能的视网膜定位图中的功能变化,测量视网膜功能的互补方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fee5/9132865/b94e4da16399/bjophthalmol-2020-318286f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fee5/9132865/84440f0a2afe/bjophthalmol-2020-318286f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fee5/9132865/98ef3b13ef6f/bjophthalmol-2020-318286f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fee5/9132865/b94e4da16399/bjophthalmol-2020-318286f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fee5/9132865/84440f0a2afe/bjophthalmol-2020-318286f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fee5/9132865/98ef3b13ef6f/bjophthalmol-2020-318286f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fee5/9132865/b94e4da16399/bjophthalmol-2020-318286f03.jpg

相似文献

1
Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec.光感受器治疗后挽救动力学的空间和时间分辨率。
Br J Ophthalmol. 2022 Jun;106(6):831-838. doi: 10.1136/bjophthalmol-2020-318286. Epub 2021 Jan 20.
2
Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.临床环境中 RPE65 基因突变相关性遗传性视网膜变性患者接受 Voretigene Neparvovec 基因增强疗法的单中心经验。
Ophthalmology. 2024 Feb;131(2):161-178. doi: 10.1016/j.ophtha.2023.09.006. Epub 2023 Sep 12.
3
Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec.使用voretigene neparvovec进行基因治疗后,黄斑中心凹的短期形态学挽救。
Acta Ophthalmol. 2022 May;100(3):e807-e812. doi: 10.1111/aos.14990. Epub 2021 Jul 21.
4
Improved Rod Sensitivity as Assessed by Two-Color Dark-Adapted Perimetry in Patients With RPE65-Related Retinopathy Treated With Voretigene Neparvovec-rzyl.接受 voretigene neparvovec-rzyl 治疗的 RPE65 相关视网膜病变患者的双色暗适应视野计评估的 Rod 敏感性提高。
Transl Vis Sci Technol. 2023 Apr 3;12(4):17. doi: 10.1167/tvst.12.4.17.
5
Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy.视网膜色素上皮 65 基因介导的遗传性视网膜营养不良的视网膜基因治疗。
Eye (Lond). 2023 Jun;37(9):1874-1877. doi: 10.1038/s41433-022-02262-5. Epub 2022 Sep 26.
6
Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice.评估 Voretigene Neparvovec 治疗效果的客观结局。
Ophthalmol Retina. 2024 Jul;8(7):688-698. doi: 10.1016/j.oret.2024.01.021. Epub 2024 Feb 1.
7
Clinical Protocols for the Evaluation of Rod Function.杆功能评估的临床方案。
Ophthalmologica. 2021;244(5):396-407. doi: 10.1159/000510888. Epub 2020 Aug 17.
8
Therapy with voretigene neparvovec. How to measure success?伏瑞替戈尼静脉输注治疗。如何衡量疗效?
Prog Retin Eye Res. 2023 Jan;92:101115. doi: 10.1016/j.preteyeres.2022.101115. Epub 2022 Sep 10.
9
Full-field Scotopic Threshold Improvement after Voretigene Neparvovec-rzyl Treatment Correlates with Chorioretinal Atrophy.经 Voretigene Neparvovec-rzyl 治疗后全视野暗点阈值改善与脉络膜视网膜萎缩相关。
Ophthalmology. 2023 Jul;130(7):764-770. doi: 10.1016/j.ophtha.2023.02.015. Epub 2023 Feb 21.
10
Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.经 RPE65 相关莱伯先天性黑矇治疗的儿科患者中 voretigene neparvovec 治疗的真实世界结局。
Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1543-1550. doi: 10.1007/s00417-021-05508-2. Epub 2022 Jan 10.

引用本文的文献

1
Progression of Dark-Adapted Visual Fields Over 3 Years in the Rate of Progression in USH2A-Related Retinal Degeneration (RUSH2A) Study.在USH2A相关视网膜变性(RUSH2A)研究中,3年期间暗适应视野的进展速度。
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):27. doi: 10.1167/iovs.66.11.27.
2
Short-Term Outcomes of Pediatric Patients With Mild Autosomal Recessive RPE65-Associated Retinal Dystrophy Treated With Voretigene Neparvovec.用维替泊芬治疗的轻度常染色体隐性RPE65相关视网膜营养不良儿科患者的短期预后
Transl Vis Sci Technol. 2025 Aug 1;14(8):8. doi: 10.1167/tvst.14.8.8.
3
Advances in Precision Therapeutics and Gene Therapy Applications for Retinal Diseases: Impact and Future Directions.

本文引用的文献

1
Chromatic Pupil Campimetry Reveals Functional Defects in Exudative Age-Related Macular Degeneration with Differences Related to Disease Activity.彩色瞳孔视野计揭示渗出性年龄相关性黄斑变性的功能缺陷,其与疾病活动度相关的差异。
Transl Vis Sci Technol. 2020 May 11;9(6):5. doi: 10.1167/tvst.9.6.5. eCollection 2020 May.
2
Clinical Protocols for the Evaluation of Rod Function.杆功能评估的临床方案。
Ophthalmologica. 2021;244(5):396-407. doi: 10.1159/000510888. Epub 2020 Aug 17.
3
Objective Measurement of Local Rod and Cone Function Using Gaze-Controlled Chromatic Pupil Campimetry in Healthy Subjects.
视网膜疾病的精准治疗与基因治疗应用进展:影响与未来方向
Genes (Basel). 2025 Jul 21;16(7):847. doi: 10.3390/genes16070847.
4
Long-term experience with gene augmentation therapy in patients with inherited retinal disease associated with biallelic mutations in .针对携带双等位基因突变的遗传性视网膜疾病患者进行基因增强疗法的长期经验。 (注:原文句末不完整,翻译根据现有内容尽量通顺表达)
Med Genet. 2025 Feb 12;37(1):47-56. doi: 10.1515/medgen-2024-2067. eCollection 2025 Apr.
5
Visual Acuity, Full-field Stimulus Thresholds, and Electroretinography for 4 Years in The Rate of Progression of USH2A-related Retinal Degeneration (RUSH2A) Study.在USH2A相关视网膜变性(RUSH2A)研究中,连续4年的视力、全视野刺激阈值和视网膜电图检查
Ophthalmol Sci. 2024 Nov 8;5(2):100648. doi: 10.1016/j.xops.2024.100648. eCollection 2025 Mar-Apr.
6
Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases.遗传性视网膜疾病基因治疗试验的临床试验终点更新
J Clin Med. 2024 Sep 18;13(18):5512. doi: 10.3390/jcm13185512.
7
Influencing Factors on Pupillary Light Responses as a Biomarker for Local Retinal Function in a Large Normative Cohort.大样本正常人群瞳孔光反射作为局部视网膜功能生物标志物的影响因素。
Invest Ophthalmol Vis Sci. 2024 Jun 3;65(6):3. doi: 10.1167/iovs.65.6.3.
8
Comparison of Full-Field Stimulus Threshold Measurements in Patients With Retinitis Pigmentosa and Healthy Subjects With Dilated and Nondilated Pupil.全视野刺激阈值测量在色素性视网膜炎患者和瞳孔扩大和未扩瞳孔的健康受试者中的比较。
Transl Vis Sci Technol. 2024 Apr 2;13(4):23. doi: 10.1167/tvst.13.4.23.
9
Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice.用于 RPE65 突变引起的遗传性视网膜营养不良的 voretigene neparvovec:从临床试验到实际实践的资格和治疗挑战的范围审查。
Eye (Lond). 2024 Sep;38(13):2504-2515. doi: 10.1038/s41433-024-03065-6. Epub 2024 Apr 16.
10
Chorioretinal Atrophy Growth After Voretigene Neparvovec Retinotopically Is Connected to Retinal Functional Rescue.维替泊苷视网膜下注射后脉络膜视网膜萎缩进展与视网膜功能挽救相关。
Transl Vis Sci Technol. 2024 Feb 1;13(2):13. doi: 10.1167/tvst.13.2.13.
在健康受试者中使用注视控制的彩色瞳孔视野计客观测量局部视杆和视锥细胞功能。
Transl Vis Sci Technol. 2019 Nov 20;8(6):19. doi: 10.1167/tvst.8.6.19. eCollection 2019 Nov.
4
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.Voretigene Neparvovec-rzyl 在 RPE65 基因突变相关性遗传性视网膜营养不良中的疗效、安全性和持久性:1 期和 3 期试验结果。
Ophthalmology. 2019 Sep;126(9):1273-1285. doi: 10.1016/j.ophtha.2019.06.017. Epub 2019 Jun 22.
5
Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version : January 2019.犬类眼科学会(DOG)、视网膜学会(RG)和英国兽医协会(BVA)关于眼科中使用voretigene neparvovec(Luxturna™)进行治疗的声明。英文版:2019年1月
Ophthalmologe. 2020 Jan;117(Suppl 1):16-24. doi: 10.1007/s00347-019-0906-2.
6
Regional Variations and Intra-/Intersession Repeatability for Scotopic Sensitivity in Normal Controls and Patients With Inherited Retinal Degenerations.正常对照者和遗传性视网膜变性患者暗适应敏感性的区域差异和内/间次重复性。
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1122-1131. doi: 10.1167/iovs.18-25473.
7
Standards in Pupillography.瞳孔测量标准。
Front Neurol. 2019 Feb 22;10:129. doi: 10.3389/fneur.2019.00129. eCollection 2019.
8
Rod and cone interactions in the retina.视网膜中的视杆细胞与视锥细胞相互作用。
F1000Res. 2018 May 23;7. doi: 10.12688/f1000research.14412.1. eCollection 2018.
9
Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.视网膜色素变性 RPE65 缺乏症基因治疗 5 年后的结果。
Hum Gene Ther. 2018 Dec;29(12):1428-1437. doi: 10.1089/hum.2018.014. Epub 2018 Jul 24.
10
Pupillographic campimetry: an objective method to measure the visual field.瞳孔视野计:一种测量视野的客观方法。
Biomed Tech (Berl). 2018 Nov 27;63(6):729-734. doi: 10.1515/bmt-2017-0029.